Comparison · NCT00430781-2349cbcc
Lapatinib Monotherapy vs Pazopanib Monotherapy: Clinical Benefit Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lapatinib Monotherapy vs Pazopanib Monotherapy: Clinical Benefit Response. Trial comparisons, record NCT00430781-2349cbcc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00430781-2349cbcc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0897 | 0.0442 | 0.174 | wilson | |
| Risk in group 2 | 0.203 | 0.127 | 0.308 | wilson | |
| Risk difference, group 1 minus group 2 | -0.113 | -0.228 | 0.000284 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.443 | 0.191 | 1.02 | log | |
| Odds ratio, group 1 over group 2 | 0.388 | 0.148 | 1.01 | log | |
| Number needed to treat, for one fewer participant with the outcome on Lapatinib Monotherapy than on Pazopanib Monotherapy | 8.85 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lapatinib Monotherapy | 1500 mg (6 x 250 mg tablets) of oral lapatinib daily | 7 | 78 | OG000 |
| Group 2 | Pazopanib Monotherapy | 800 mg (2 x 400 mg tablets) of oral pazopanib daily | 15 | 74 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Clinical Benefit Response
- Description
Clinical benefit response is defined as the number of participants with evidence of complete (CR) or partial (PR) tumor response or stable disease (SD) for at least 6 months (183 days). Per Response Evaluation Criteria In Solid Tumors (RECIST): CR, all detectable tumor has disappeared; PR, a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum; Stable Disease, small changes that do not meet previously given criteria. Confirmation requires at least 2 assessments of CR/PR with at least 4 weeks between assessments.
- Time frame
- From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)
- Population
- ITT Population
Source ClinicalTrials.gov
Trial
- Title
- Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
- NCT number
- NCT00430781
- Phases
- PHASE2
- Conditions
- Neoplasms, Uterine Cervix, Metastatic Cervical Cancer
- Interventions
- pazopanib (GW786034), lapatinib (GW572016)
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2011-03-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00430781?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00430781-2349cbcc